Eisai Inc. Sustainability Profile
Eisai Inc., a prominent player in the pharmaceutical industry, is headquartered in the United States and operates extensively across North America and beyond. Founded in 1941, Eisai has established itself as a leader in the development of innovative treatments, particularly in neurology and oncology. The company is renowned for its core products, including the Alzheimer's treatment Aricept and the anti-cancer agent Lenvima, both of which exemplify Eisai's commitment to addressing unmet medical needs. With a strong focus on research and development, Eisai has achieved significant milestones, including numerous FDA approvals and partnerships that enhance its market position. The company's dedication to patient-centric solutions and its unique approach to drug development underscore its reputation as a trusted name in healthcare, making Eisai Inc. a vital contributor to advancements in medical science.
DitchCarbon Score
How does Eisai Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Eisai Inc.'s score of 62 is higher than 76% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Eisai Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Eisai Co., Ltd., which may influence its climate commitments and emissions reporting. Eisai Co., Ltd. has set various climate initiatives that cascade down to Eisai Inc. These include participation in the Science Based Targets initiative (SBTi), the Carbon Disclosure Project (CDP), and the RE100 initiative, all aimed at enhancing sustainability and reducing carbon footprints. However, specific reduction targets or achievements for Eisai Inc. have not been disclosed. As part of its commitment to climate action, Eisai Co., Ltd. is actively working towards reducing its overall environmental impact, although detailed metrics and specific targets for Eisai Inc. remain unspecified. The absence of emissions data highlights the need for further transparency in reporting and commitment to climate goals within the organisation.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 49,457,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 55,830,000 | 00,000,000 | 00,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | 456,386,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
How Carbon Intensive is Eisai Inc.'s Industry?
How Carbon Intensive is Eisai Inc.'s Location?
Eisai Inc.'s Scope 3 Categories Breakdown
Eisai Inc.'s Scope 3 emissions, which decreased by 6% last year and increased by approximately 24% since 2019, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" representing nearly all of their reported Scope 3 footprint.
Top Scope 3 Categories
Eisai Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Eisai Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
